Online inquiry

IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9444MR)

This product GTTS-WQ9444MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets KIR3DL2 gene. The antibody can be applied in Lymphoma, cutaneous T cell (CTCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001242867.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3812
UniProt ID P43630
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9444MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13314MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ13863MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ12456MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ13538MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRX-003
GTTS-WQ11734MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ7072MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ11170MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ1903MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGEN2034
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.